The immunoglobulin light chain is the small polypeptide subunit of an antibody. There are two types of light chain in humans,kappa (κ) chain and lambda (λ) chain. Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. It can be detected with varying frequencies in other B-cell malignancies such as chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma(NHL).
|CAT||Product Name||Target Species||Antibody Clone||Antibody Host||Receptor Construction||Vector Type||Targeting Cell Type||Inquiry & Datasheet|
|CAR-LC217||Anti-Kappa light chain h(41BB-CD3ζ) CAR, pCDCAR1||Human||Mouse||scFv-41BB-CD3ζ||Lentiviral||T cell|
|CAT||Product Name||Clone||Promotor||Packaging System||Targeting Diseases||Inquiry & Datasheet|
|VP-CAR-LC692||Lenti-Kappa light chain CAR (scFv-41BB-CD3ζ) Viral Particle||EF1a||Lentivirus|
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE